FC
CTXR icon

Fairscale Capital’s Citius Pharmaceuticals CTXR Stock Holding History

Fairscale Capital’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25 Hold
42
– – ﹤0.01% 440
2026
Q1 		$38 Hold
42
– – ﹤0.01% 436
2025
Q4 		$33 Hold
42
– – ﹤0.01% 426
2025
Q3 		$52 Hold
42
– – ﹤0.01% 442
2025
Q2 		$58 Hold
42
– – ﹤0.01% 439
2025
Q1 		$63 Sell
42
-324
-89% -$775 ﹤0.01% 350
2024
Q4 		$1.46K Hold
366
– – ﹤0.01% 317
2024
Q3 		$4.58K Hold
366
– – ﹤0.01% 274
2024
Q2 		$7.78K Buy
+366
New +$6.56K 0.01% 267

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM

Fairscale Capital's CTXR Position: Q2 2026 in Review

Fairscale Capital held its Citius Pharmaceuticals (CTXR) position steady in Q2 2026 at 42 shares worth $25. The position accounts for ﹤0.01% of the portfolio, ranked #440.

Fairscale Capital first reported a position in CTXR in Q2 2024 and has held it in 9 quarters since. The position peaked at $7.78K in Q2 2024. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • Fairscale Capital held 42 shares of Citius Pharmaceuticals worth $25 as of Q2 2026.
  • Fairscale Capital left its Citius Pharmaceuticals share count unchanged in Q2 2026.
  • Citius Pharmaceuticals made up ﹤0.01% of Fairscale Capital's portfolio in Q2 2026, its #440 holding.
  • Fairscale Capital first reported a position in Citius Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Fairscale Capital's Citius Pharmaceuticals position peaked at $7.78K in Q2 2024.
  • 43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Fairscale Capital's 13F filing for Q2 2026, filed 7 Aug 2026.